Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 19/20 | 0.61 |
| ▸ | EED | O75530 | 5/20 | 0.53 |
| ▸ | RBBP4 | Q09028 | 5/20 | 0.53 |
| ▸ | SUZ12 | Q15022 | 5/20 | 0.53 |
| ▸ | AEBP2 | Q6ZN18 | 5/20 | 0.53 |
| ▸ | EZH1 | Q92800 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14726791 | 0.99 | EZH2 (0.61) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL2586392 | 0.96 | EZH2 (0.58) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL12180148 | 0.92 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL12180270 | 0.92 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL19620847 | 0.91 | EZH2 (0.61) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL12180273 | 0.89 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL12180179 | 0.89 | EZH2 (0.59) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17229172 | 0.88 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL12180078 | 0.87 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17970398 | 0.87 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | claimed |
| EP-2773754-B1 | Compounds for use in the treatment of T-cell mediated diseases | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-08-03 | — | — | EP | claimed |
| US-9402836-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2016-08-02 | — | — | US | claimed |
| US-20150313887-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2015-11-05 | — | — | US | claimed |
| US-8975291-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2015-03-10 | — | — | US | claimed |
| US-20130345200-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2013-12-26 | — | — | US | claimed |
| EP-3246027-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF CANCER | GlaxoSmithKline LLC (US) | 2017-11-22 | — | — | EP | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649307-B2 | Indoles | GLAXOSMITHKLINE LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160296518-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2016-10-13 | — | — | US | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013067296-A1 | METHOD OF TREATMENT | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (No 2) LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
| EP-2566327-A1 | INDOLES | GlaxoSmithKline LLC (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053397-A1 | INDOLES | GLAXOSMITHKLINE LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011140324-A1 | INDOLES | GLAXOSMITHKLINE LLC (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150313887-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EED 3322/4885RBBP4 2305/4885 |
| US-20130345200-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EED 3322/4885RBBP4 2305/4885 |
| US-20130053397-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 239/4885EED 3258/4885RBBP4 2182/4885 |
| US-20160296518-A1 | INDOLES | IDO1, IDO2, INMT | EZH2 257/4885EED 3322/4885RBBP4 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.